PLYX · Polaryx Therapeutics, Inc.
$1.91
-0.08 (-4.02%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.”View the 10-Q filed May 15, 2026
Market Cap
$94.21M
Shares
47.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$8.99M
+70.4%
FY2025
Diluted EPS
-$0.20
+77.5%
FY2025
Operating Cash Flow
-$3.94M
-53.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $6.27M | $2.81M | |
| $1.56M | $1.54M | |
| $7.82M | $4.35M | |
| -$7.82M | -$4.35M | |
| -$8.99M | -$30.36M | |
| -$8.99M | -$30.36M | |
| USD/shares | -$0.20 | -$0.89 |
| USD/shares | -$0.20 | -$0.89 |
| shares | 45.42M | 34.2M |
| shares | 45.42M | 34.2M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.